Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

125.85 +2.35 (+1.90%)

Streaming Delayed Price Updated: 1:24 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

'Buy Long Duration Bonds,' Says Bank Of America Strategist: 4 ETFs To Watch As Trump's Deficit Fight Unfolds ↗

January 17, 2025

Investors may be underestimating Trump's potential push for fiscal discipline, making long-term bonds and rate-sensitive sectors attractive bets.

Via Benzinga

Topics Bonds ETFs Government

We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks ↗

January 15, 2025

Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover.

Via Stocktwits

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗

January 15, 2025

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Via Stocktwits

I’m Not Worried About This Pullback ↗

January 08, 2025

Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree.

Via Talk Markets

Topics Cryptocurrencies Stocks / Equities

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗

January 06, 2025

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

Via Talk Markets

Topics ETFs Stocks / Equities

No Value In Value? Stock Market (And Sentiment Results) ↗

January 02, 2025

In a year like 2024, it is easy to forget the fact that since 1927 “Value” has outperformed “Growth” by 4.4% per year:

Via Talk Markets

Topics Stocks / Equities

Healthcare And Biotech Stocks Continue Their Slide ↗

December 30, 2024

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

Via Talk Markets

Topics ETFs Stocks / Equities

Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market? ↗

December 23, 2024

It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force.

Via Talk Markets

Topics ETFs Stocks / Equities

20 ETFs Primed For Unusually Big Swings On Fed Meeting Days ↗

December 18, 2024

The Federal Reserve's final meeting of the year has historically caused significant moves in 20 ETFs. A rate cut is expected, but the focus is on the Fed's forward guidance and projections.

Via Benzinga

Topics ETFs Economy

It’s Been A Tough Month For Healthcare Stocks ↗

December 02, 2024

It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.

Via Talk Markets

Topics ETFs Stocks / Equities

As The Market Churns ↗

November 26, 2024

Stocks managed to grind their way higher on the day, while rates and the dollar rebounded from yesterday’s declines.

Via Talk Markets

Topics ETFs Stocks / Equities

Momentum Model For Trading SMID Biotech Stocks: Broad Rally Underway ↗

November 25, 2024

Biotech stocks are poised for a recovery in a seasonally strong period through January 2025.

Via Talk Markets

Topics ETFs Stocks / Equities

Is Biotech’s Bull Run Over? Examining Election Impacts

November 21, 2024

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

Via MarketBeat

Topics ETFs Government

What To Do After The Worst Week For Healthcare Stocks Since March 2020? ↗

November 19, 2024

The market was quiet today but we should still expect some gains through year -end albeit a bit choppy.

Via Talk Markets

A Must See Chart For Prudent Investors, Trump To Help Tesla Dominate, Nvidia Heat Problem ↗

November 18, 2024

To gain an edge, this is what you need to know today.

Via Benzinga

Topics Government

Post-Election Euphoria Turns Into Hangover; One New Swing Position ↗

November 16, 2024

In this video, I take a look at how the markets have turned around after the US election. I also review a new long setup in Pinnacle West Capital.

Via Talk Markets

Biotech Stocks Are Rallying: What Is Your Playbook? ↗

November 11, 2024

If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.

Via Talk Markets

Wednesday's Rally Followed By Friday's ↗

November 09, 2024

Everyone who follows the stock market knows that a huge rally occurred on Wednesday, and by Friday, new highs were set for many of the most important stocks, ETFs, and Indexes. Tuesday's rally off the...

Via Talk Markets

Topics ETFs

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking? ↗

November 06, 2024

Donald Trump won his second presidency in a victory over Kamala Harris. What can investors in biotech stocks expect?

Via Investor's Business Daily

Topics Government

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Biotech Momentum Trades For The Q4 Rally ↗

October 29, 2024

The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.

Via Talk Markets

AskSlim Market Week - Friday, Oct. 25 ↗

October 25, 2024

An analysis and commentary on the financial markets.

Via Talk Markets

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗

October 14, 2024

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Via Talk Markets

Stocks Drop On October 7, And Are Poised To Move Lower ↗

October 07, 2024

The S&P 500 fell 90 bps today, closing at 5695, bringing the zero gamma level back into focus. This area has strong support, primarily because it separates the post-FOMC gap higher from the current...

Via Talk Markets

Topics Stocks

Biotech Stocks Poised For Another Big Move In Q4 ↗

October 07, 2024

The healthcare sector can be a safe haven if volatility increases.

Via Talk Markets

Biotech Stocks : Are You A Trader Or A Longer Term Investor? ↗

October 01, 2024

Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.

Via Talk Markets

BCYC: A Promising Play In The Biotech Sector ↗

October 01, 2024

The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a...

Via Talk Markets

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.